1. Medtech Insight
  2. >>Geography
  3. >>Europe

Bisazza To Take The Helm As CEO of MedTech Europe From Early 2023

 
• By Amanda Maxwell

There is to be a smooth transition at the top of the EU’s largest medtech industry association as news emerges that Oliver Bisazza will step into the CEO position from early January.

A businessman appoints a leader to the head of the team. Creation of an effective teams of specialists for the implementation of a new project. HR recruiting. Management appointment. nepotism
• Source: Shutterstock/ Andrii Yalanskyi

Oliver Bisazza has been named the new CEO of MedTech Europe with effect from 2 January 2023. He will succeed Serge Bernasconi who announced earlier this year that he was due to be retiring after over 10 years at the helm when the right person could be found to replace him.

Bisazza is currently director general industrial policies & external affairs at MedTech Europe and a and well-respected spokesman for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Swiss Medtech To Battle ‘Arbitrary’ 39% US Tariff

 
• By Ashley Yeo

In return for building a successful US export business, Switzerland has been handed a 39% tariff effective immediately by the Trump administration. Diplomatic channels have been reopened to undo the tariff. Meanwhile, the medtech industry is looking to develop OUS markets for Swiss exporters.

Injuries And Deaths Linked To Boston Scientific Cardiac Devices. Company Responds

 
• By Brian Bossetta

The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

 
• By Marion Webb

HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.